Pooled outcomes for this meta-analysis. حسب Danni Jiang (1722013)

الموضوعات:

Pooled results for each outcome. حسب Danni Jiang (1722013)

الموضوعات:

Pooled results for each outcome. حسب Danni Jiang (1722013)

الموضوعات:

The fraction of predicted heterozygotes that are set to “No Call” by RHA decreases as the size of the heterozygote cluster increases. حسب Orna Mizrahi-Man (42539)

Statistically significant differences in the time points post treatment compared to baseline. حسب Suzanne N. King (12542539)

Tumor growth trajectories and the response to different treatments. حسب Chi-Feng Chiang (16534951)

الموضوعات:

Regenerating axons are increased by ATRA and decreased by clodronate. حسب Valeria De La Rosa-Reyes (6658613)

Running intervals. حسب Craig P. Smith (9322458)

Switching patterns of ICS/LABA. حسب Rieko Kondo (10010647)

الموضوعات:

Factors associated with exacerbations. حسب Rieko Kondo (10010647)

الموضوعات:

Definition of each exacerbation. حسب Rieko Kondo (10010647)

الموضوعات:

Definitions of treatment step classification. حسب Rieko Kondo (10010647)

الموضوعات:

Sensitivity analyses of breakthrough exacerbations. حسب Rieko Kondo (10010647)

الموضوعات:

Baseline characteristics of patients. حسب Rieko Kondo (10010647)

الموضوعات:

Data for primary and sensitivity analysis. حسب Rieko Kondo (10010647)

الموضوعات:

Study design. حسب Rieko Kondo (10010647)

الموضوعات:

Odds ratios for each case period compared with the control period. حسب Rieko Kondo (10010647)

الموضوعات:

Sensitivity analysis of the group who had an exacerbation before the index date. حسب Rieko Kondo (10010647)

الموضوعات:

Initial post-switch visits and SABA prescriptions in each period. حسب Rieko Kondo (10010647)

الموضوعات:

Flow of eligible patients. حسب Rieko Kondo (10010647)

الموضوعات: